Technology for type 1 diabetes: what impact will it have?
Technological advances have profoundly affected people living with type 1 diabetes, their families or carers, and health-care systems. The innovations include the development of analogue insulins, continuous glucose monitoring (CGM) devices, applications that support carbohydrate counting and insulin dosing, insulin pumps, hybrid closed-loop therapy, and telemedicine. Multiple clinical trials1–3 and systematic reviews4,5 have demonstrated clinically relevant benefits of hybrid closed-loop therapy, but it is well established that trial participants and the intense clinical care scenario in which they participate within the trial might not be generalisable to the broader population of people with type 1 diabetes.
